PRLog (Press Release)
- Jan. 27, 2014 - NEW YORK --
A Comparative Melanoma Tumor Board Study conducted over 2 1/2 years by the National Cancer Institute in Bethesda, MD and sponsored by the Animal Cancer Foundation recently identified striking similarities between naturally occurring malignant melanomas in pet dogs and a highly fatal subgroup of human mucosal melanomas. The collaborative board comprised of both physician and
veterinary experts in the diagnosis and treatment of melanomas in both species, led by patholdogists R. Mark Simpson, D.V.M., Ph.D. and Stephen M. Hewitt, M.D., Ph.D., concluded that many shared clinical, pathological, and certain molecular features of this cancer make melanoma-bearing dogs good candidates for canine clinical trial designed to find new treatments to benefit humans with melanomas as well as the pets themselves.
The hallmark study, creating an unprecendented synergy between world experts in melanomas affecting both people and pets, was recently published in the scientific journal, Pigment Cell & Melanoma Research
, the official journal of the Society for Melanoma Research [http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12185/full
]. In conjunction with publication, Animal Cancer Foundation sponsored a Society for Melanoma Research Workshop, November 20, 2013 in Philadelphia at the Society's annual meeting. The workshop session moderated by Marcus Bosenberg, M.D., Ph.D., of Yale University, highlighted the findings and featured presentations of developing directions to establish new treatments for dogs and humans with melanoma by Jeffrey Trent, Ph.D., President & Research Director of Translational Genomics Research Institute (TGen), Phoenix, AZ, Catherine Andre, Ph.D., Principal Investigator of the Canine Genetics Group of the University of Rennes, Rennes, FR, and Cheryl London, D.V.M., Ph.D.m Professor and veterinary oncologist, The Ohio State University, Columbus, OH. This comparative model represents an important step forward for the many pets and people diagnosed with melanoma.